Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02520011 · ClinicalTrials.gov registry record · Phase 2
Alvocidib Biomarker-driven Phase 2 AML Study
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Terminated
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT02520011 is a Phase 2 study that was terminated before completion, run by Sumitomo Pharma America. The registered enrollment target is 104 participants.
The verdict
NCT02520011, a Phase 2 study, was terminated before completion, sponsored by Sumitomo Pharma America.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete Remission) of ACM (Alvocidib/Cytarabine/Mitoxantrone) compared to CM (Cytarabine/Mitoxantrone) treatment in refractory or relapsed AML patients with demonstrated MCL-1 dependence of ≥ 30% by mitochondrial profiling in bone marrow.
Interventions
- DRUG Cytarabine
- DRUG Mitoxantrone
- DRUG Alvocidib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2016-03-14 |
| Est. Completion | 2020-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02520011
The ClinicalTrials.gov registry entry for NCT02520011 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cytarabine is the first listed.
NCT02520011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02520011 about?
NCT02520011 is a clinical study titled "Alvocidib Biomarker-driven Phase 2 AML Study". The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete Remission) of ACM (Alvocidib/Cytarabine/Mitoxantrone) compared to CM (Cytarabine/Mitoxantrone) treatment in refractory or relapsed AML patients with demonstrated MCL-1 dependence of ≥ 30% by mitochondrial profil...
What is the current status of trial NCT02520011?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2016-03-14. Estimated completion is 2020-02-12.
What interventions are being tested in trial NCT02520011?
The interventions under investigation include: Cytarabine (DRUG), Mitoxantrone (DRUG), Alvocidib (DRUG).
Who is sponsoring clinical trial NCT02520011?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.